支气管扩张症

Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax. 1950;5:233-247.

• 全文
• 摘要

Rosen MJ. Chronic cough due to bronchiectasis. ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1_Suppl):122S-131S.

• 全文
• 摘要

Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(suppl 1):i1-i58.

• 全文
• 摘要

Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260-1267.

• 全文
• 摘要

Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186:657-665.

• 摘要

Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576-585.

• 全文
• 摘要

1.  Laennec RT. A treatise on the disease of the chest. Forbes J, trans. New York, NY: Macmillan (Hafner Press);1962:78.

2.  Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax. 1950;5:233-247.

• 全文
• 摘要

3.  Rosen MJ. Chronic cough due to bronchiectasis. ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1_Suppl):122S-131S.

• 全文
• 摘要

4.  Barker AF. Bronchiectasis. New Engl J Med. 2002;346:1383-1393.

• 摘要

5.  Liebow AA, Hales MR, Lindskog GE. Enlargement of the bronchial arteries, and their anastomoses with the pulmonary arteries in bronchiectasis. Am J Pathol. 1949;25:211-231.

• 全文
• 摘要

6.  Weyker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205.

7.  Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432-439.

• 全文
• 摘要

8.  British Thoracic Society Standards of Care Committee. BTS statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease. Thorax. 2008;63(suppl 1):i1-i16.

• 全文
• 摘要

9.  Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child. 2005;90:737-740.

• 摘要

10.  McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012;142:159-167.

• 摘要

11.  Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long term study assessing the factors influencing survival. Eur Respir J. 2009;34:843-849.

• 摘要

12.  Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277-1284.

• 摘要

13.  Cole PJ. Host microbe relationships in chronic respiratory infection. Respiration. 1989;55(suppl 1):5-8.

• 摘要

14.  Morrissey BM. Pathogenesis of bronchiectasis. Clin Chest Med. 2007;28:289-296.

• 摘要

15.  Burgel PR, Montani D, Danel C, et al. A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax. 2007;62:153-161.

• 摘要

16.  Rodman DM. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Resp Crit Care Med. 2005;171:621-626.

• 摘要

17.  Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med. 1995;333:431-440.

• 摘要

18.  Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48.

• 摘要

19.  Hartl D, Latzin P, Zissel G, et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006;173:1370-1376.

• 摘要

20.  Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989;321:863-868.

• 摘要

21.  Friedman KJ, Teichtahl H, De Kretser DM, et al. Screening Young syndrome patients for CFTR mutations. Am J Respir Crit Care Med. 1995;152:1353-1357.

• 摘要

22.  Le Mauviel L. Primary ciliary dyskinesia. West J Med. 1991;155:280-283.

• 全文
• 摘要

23.  Bush A, Cole P, Hariri M, et al. Primary ciliary dyskinesia: diagnosis and standards of care. Eur Resp J. 1998;12:982-988.

• 全文
• 摘要

24.  Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med. 2013;188:913-922.

• 全文
• 摘要

25.  Cuvelier A, Muir JF, Hellot MF, et al. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest. 2000;117:415-419.

• 全文
• 摘要

26.  McMahon MJ, Swinson DR, Shettar S, et al. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis. 1993;52:776-779.

• 摘要

27.  Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J. 2000;15:5-10.

• 全文
• 摘要

28.  Silva JR, Jones JA, Cole PJ, et al. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax. 1989;44:668-673.

• 全文
• 摘要

29.  Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178:1066-1074.

• 全文
• 摘要

30.  Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995;108:955-961.

• 全文
• 摘要

31.  Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(suppl 1):i1-i58.

• 全文
• 摘要

32.  Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. 2007;99:462-464.

• 摘要

33.  Verghese A. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. Arch Intern Med. 1994;154:2086-2091.

• 摘要

34.  Hansell DM. Bronchiectasis. Radiol Clin North Am. 1998;36:107.

• 摘要

35.  Hansell DM. Imaging of diseases of the chest. 4th ed. Philadelphia, PA: Elsevier Mosby; 1995.

36.  Konstan MW, Morgan WJ, Butler SM, et al.; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151:134-139.

• 摘要

37.  Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 2007;42:525-532.

• 摘要

38.  Rivera M. Pseudomonas aeruginosa mucoid strain. Its significance in adult chest diseases. Am Rev Respir Dis. 1982;126:833-836.

• 摘要

39.  Stoller JK, Aboussouan LS. Alpha 1-antitrypsin deficiency. Lancet. 2005;365:2225-2236.

• 摘要

40.  Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2015;(11):CD008351.

• 全文
• 摘要

41.  Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34:1086-1092.

• 摘要

42.  Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012;106:661-667.

• 摘要

43.  Reeves EP, Williamson M, O'Neill SJ, et al. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011;183:1517-1523.

• 全文
• 摘要

44.  Bilton D, Daviskas E, Anderson SD, et al; B301 Investigators. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013;144:215-225.

• 全文
• 摘要

45.  Bilton D, Tino G, Barker AF, et al; B-305 Study Investigators. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014;69:1073-1079.

• 摘要

46.  Hart A, Sugumar K, Milan SJ, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2014;(5):CD002996.

• 全文
• 摘要

47.  Crasafulli E, Colettu O, Costi S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day prospective, parallel, open- label, pilot study. Clin Ther. 2007;29:2001-2009.

• 摘要

48.  Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014;(5):CD001289.

• 全文
• 摘要

49.  McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(suppl 1):250S-259S.

• 全文
• 摘要

50.  Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax. 2005;60:943-948.

• 摘要

51.  Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007;101:1390.

• 摘要

52.  Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-1259.

• 摘要

53.  Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260-1267.

• 全文
• 摘要

54.  Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-667.

• 摘要

55.  White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med. 2012;106:356-360.

• 全文
• 摘要

56.  Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186:657-665.

• 摘要

57.  Murray MP, Govan JR, Doherty CJ, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183:491-499.

• 摘要

58.  Hnin K, Nguyen C, Carson KV, et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev. 2015;(8):CD001392.

• 全文
• 摘要

59.  Chang KC, Leung CC, Yew WW, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur Respir J. 2010;35:606-613.

• 摘要

60.  Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60:239-243.

• 摘要

61.  Zhang P, Jiang G, Ding J, et al. Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients. Ann Thorac Surg. 2010;90:246-250.

• 摘要

62.  Bagheri R, Haghi SZ, Fattahi Massoum SH, et al. Surgical management of bronchiectasis: analysis of 277 patients. Thorac Cardiovasc Surg. 2010;58:291-294.

• 摘要

63.  Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1-15.

• 全文
• 摘要

64.  Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481-485.

• 全文
• 摘要

65.  Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189:975-982.

• 全文
• 摘要

66.  Scheinberg P, Shore E; PC-TNDS-008 Study Group. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005;127:1420-1426.

• 全文
• 摘要

67.  Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013;41:1107-1115.

• 全文
• 摘要

68.  Serisier DJ, Bilton D, De Soyza A, et al; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68:812-817.

• 摘要

69.  Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013;107:524-533.

• 摘要

70.  Keistinen T, Saynajakangas O, Tuuponen T, et al. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J. 1997;10:2784-2787.

• 全文
• 摘要

71.  Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565-1572.

• 摘要

72.  Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576-585.

• 全文
• 摘要

73.  Ellis HC, Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J. 2016;47:482-489.

• 摘要

74.  McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016 Aug 11 [Epub ahead of print].

• 全文
• 摘要

75.  Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128:739-745.

• 全文
• 摘要

76.  Fartoukh M, Khalil A, Louis L, et al. An integrated approach to diagnosis and management of severe haemoptysis in patients admitted to the intensive care unit: a case series from a referral center. Respir Res. 2007;8:11.

• 全文
• 摘要

77.  Serasli E, Kalpakidis V, Iatrou K, et al. Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes. Int Angiol. 2008; 27:319-328.

• 摘要